Bavarian Nordic's Q3 sales stall at DKK 1.8bn as rabies and chikungunya shots grow
The Danish vaccine maker reported no year-on-year revenue change for the quarter, with its travel franchise growing while government-supplied products contributed DKK 606m.
Bavarian Nordic reported third-quarter 2026 revenue of DKK 1,805 million, the same as in the corresponding quarter of 2025. The result was driven by the company's travel vaccine business, which grew 22%.
The company attributed that growth to its rabies vaccine, sold as RabAvert and Rabipur, and to the launch of its chikungunya vaccine, Vimkunya. The disclosure does not break out sales for either product.
The Public Preparedness segment, which covers vaccines supplied to governments, contributed DKK 606 million, roughly a third of group revenue for the quarter. The company did not give a prior-year comparison for the segment in the information available.
Bavarian Nordic left its full-year outlook as it stood after an earlier increase: revenue of about DKK 6,100 million and an EBITDA margin of around 32%.
The company also noted that in August the European Commission approved its MVA-BN vaccine, used against mpox and smallpox, for children aged 2 to under 12. It added that its chief financial officer is planned to leave in April 2027; no successor was mentioned.
Why it matters
- A flat quarter with a 22% travel gain suggests growth in that business is being offset elsewhere in the group, though the disclosure does not say where.
- Vimkunya is now contributing to sales, an early commercial marker for the chikungunya vaccine alongside the established rabies franchise.
- The August EU approval for MVA-BN in children aged 2 to under 12 widens the vaccine's labelled population in Europe; the disclosure gives no sales estimate for it.
- A planned CFO departure in April 2027 gives the company several months to manage a finance leadership change.
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
